Hanmi Pharmaceutical

Divers with higher-risk patent foramen ovale are especially susceptible to decompression illness and should consider conservative diving practices, researchers say.

The first small-molecule glucagon-like peptide 1 receptor agonist to complete a phase 3 trial lowers A1c and reduces weight, the company says.

Development of IDH inhibitors has changed the treatment landscape

BOSTON, September 09, 2022--Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection

Korean randomized trial shows hard endpoint benefit without a difference in bleeding

Lower-intensity therapies now available and effective for these patients

Early initiation of this approach should be considered in patients with challenging lipid disorders who are at increased risk of atherosclerotic cardiovascular disease events, observers say.